Market Report for Antibiotics Targeting Multidrug-Resistant Bacteria & Gram-Negative Organisms

Aug. 23, 2013 - PRLog -- Dallas, TX, August 22, 2013  -  Since their discovery almost a century ago, antibiotics have revolutionized the global healthcare industry by ushering in an era of significantly reduced morbidity and mortality associated with often-lethal bacterial infections. However, the increasing threat posed by multidrug-resistant (MDR) bacteria, in particular gram-negative organisms, has cast a shadow over these remarkable public health achievements. GlobalData’s primary research indicates that this high level of unmet need has generated several opportunities for firms seeking access to the market. These opportunities include leveraging microbiological diagnostics to streamline research and development (R&D) and clinical applications, discovering antimicrobial biologics, exploring alternative preclinical testing environments, enhancing the activity of existing antibiotics, and utilizing probiotics and the natural flora. GlobalData expects that the increasing rates of drug-resistant infections will continue to drive the growth of the antibiotic market in both the US and the 5EU.

Complete report available @ http://www.rnrmarketresearch.com/pharmafocus-market-acces....

Incentive Programs Are Helping Make Antibiotics an Attractive Therapy Area

Many large pharmaceutical companies abandoned antibiotics due to the drugs’ risky, prolonged R&D process, combined with relatively low prices and short duration of therapy. This has resulted in a stagnant pipeline and has limited the ability of physicians to treat MDR-bacterial infections. The Generating Antibiotic Incentives Now (GAIN) Act, which was passed in the US in 2012, exemplifies an initiative that is intended to drive antibiotic innovation and R&D. Public and private entities are also launching programs to encourage basic research and drug discovery.

The limited variety of current programs is hindering the impact of these initiatives, but GlobalData believes that a mixture of push, pull, and hybrid mechanisms will encourage progress throughout all the stages of antibiotic development.

 The FDA and EMA Appear Receptive to Aligning Clinical Trial Design and Endpoints to Address Unmet Clinical Needs

According to key opinion leaders (KOLs) interviewed by GlobalData, an outdated and disjointed regulatory landscape across the US and EU has served as a daunting barrier to accessing the marketplace. Given the wide range of indications and pathogens treated by antimicrobial agents, a detailed discussion of indication-specific regulatory requirements is beyond the scope of this report.

Rather, this report focuses on important overarching trends in the regulatory landscape, led primarily by the evolving stances of the Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

GlobalData’s primary research revealed that both agencies are trending towards increased flexibility, with the goal of better aligning antibiotic approval and labeling mechanisms with unmet medical need. Steps towards this goal include more pragmatic clinical trial endpoints and enrollment criteria, the active engagement of sponsors, and establishing regulatory accord across the US and Europe regarding approval criteria (for example, the Transatlantic Taskforce on Antimicrobial Resistance [TATFAR]). GlobalData believes that firms seeking to enter the market must foster continuous dialogue with the FDA and EMA in order to streamline the clinical development process.

 Antibiotic R&D Requires a Partnership Approach

GlobalData believes that the disappearance of Big Pharma from antibiotic R&D is due to the failure of the traditional business model, where a single company would discover, develop, and launch an antibiotic. Given the current state of the market and declining revenue streams associated with antibacterials, the risks associated with this type of venture are no longer justified. GlobalData believes that a “partnership approach,” where financial risk is distributed among multiple stakeholders by incentivizing larger companies back into the field through public-private partnerships (PPPs), represents a realistic, balanced approach to the development of novel antibiotics. 

In this collaborative model, Big Pharma will foster relationships with academic labs and small and medium enterprises (SMEs) to conduct early-stage R&D, predominantly discovery and preclinical studies, while leveraging its own late-stage R&D expertise to more efficiently push drug candidates through clinical trials. GlobalData also expects incentive programs, such as the GAIN Act and the Biomedical Advanced Research and Development Authority (BARDA), to help facilitate this shift away from the traditional R&D approach. Importantly, financial backing from governments will play a role in all stages of the R&D process. GlobalData believes that PPPs will be a key driver of the MDR gram-negative market in the US and EU, replacing blockbuster drugs with more niche products that possess more modest returns on investment (ROIs), but address clinical unmet needs.

What Do Physicians and Researchers Think?
“By far, the biggest unmet need at this point is to work on the treatment of the highly resistant gram-negative bacteria.”

US Key Opinion Leader, June 2013
“Anything we can do for the patient, rather than giving broad-spectrum or general antibiotics…the sooner we can identify the pathogen, and sensitivity will speed up the process, and you’ll get better clinical outcomes.”

EU Key Opinion Leader, June 2013
“Industry is not monolithic. Small companies need different things than medium companies, as well as big companies, and frankly, even among big companies, different big companies want different things. AstraZeneca is very interested in unmet need pricing to drive their drug development. GSK [GlaxoSmithKline] is not. GSK is much more interested in push incentives. So, AstraZeneca is interested in pull [incentives], and GSK is interested in PPPs and push [incentives].”

 

US Key Opinion Leader, June 2013 

About RnRMarketResearch.com:
RnRMarketResearch.com is an online market research reports library of 250,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers. RnR Market Research also offers company data, country profiles, trends, information and analysis on the sector of your interest.

Contact:
Priyank Tiwari
RnRMarketResearch.com
17304, Preston Road,
Suite 800, Dallas TX 75252.
+1 888 391 5441
sales@rnrmarketresearch.com
http://www.rnrmarketresearch.com